Welcome to our dedicated page for Supernus Pharmaceuticals news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharmaceuticals stock.
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is a leading specialty pharmaceutical company dedicated to developing and commercializing innovative products for the treatment of central nervous system (CNS) disorders. With over two decades of experience in the industry, Supernus has made significant strides in neurology and psychiatry.
Supernus’ product portfolio is diverse, including approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. Flagship products include Trokendi XR®, Oxtellar XR®, Qelbree®, APOKYN®, XADAGO®, MYOBLOC®, GOCOVRI®, and Osmolex ER®.
In 2013, Supernus successfully launched two groundbreaking products: Oxtellar XR® and Trokendi XR®, both aimed at treating epilepsy. These innovative formulations offer extended-release solutions, enhancing patient convenience and compliance.
Beyond these milestones, Supernus is actively developing new therapeutic candidates in psychiatry to address unmet medical needs in ADHD, depression, and their co-existing disorders. The company leverages proprietary and in-licensed technologies to create differentiated products. By focusing on known drug compounds with established mechanisms of action, Supernus minimizes the risks, costs, and time associated with new drug development.
Supernus has recently announced notable developments:
- Financial and business results for Q4 and the full year of 2023 will be reported on February 27, 2024.
- Actress Busy Philipps has partnered with Supernus to raise awareness about ADHD during Mental Health Awareness Month, spotlighting Qelbree® as a non-stimulant medication for ADHD.
- Supernus signed an exclusive licensing agreement with M8 Pharmaceuticals to commercialize Qelbree® in Latin America, expanding its reach and impact.
With a strong foundation and ongoing projects, Supernus Pharmaceuticals continues to make significant contributions to the field of CNS disorders, enhancing patient lives through innovative solutions.
Supernus Pharmaceuticals will present an overview and update at the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 2:00 p.m. ET. Investors can schedule virtual meetings with management during the conference. A live webcast of the presentation will be available on the company's website, with a replay accessible for 60 days post-conference. Supernus focuses on developing products for central nervous system diseases, including treatments for migraine, epilepsy, Parkinson’s disease, and chronic sialorrhea.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced its participation in the Wells Fargo 2020 Virtual Healthcare Conference on September 9, 2020, at 9:20 a.m. ET. The company will provide an overview and update, along with hosting investor meetings. Interested investors can arrange virtual meetings by contacting the conference coordinator. A live webcast of the presentation will be available on the company's website, with an archived replay accessible for 60 days post-conference.
Supernus focuses on treatments for CNS diseases and has multiple marketed products and development candidates.
Supernus Pharmaceuticals (SUPN) reported Q2 2020 revenues of $126.7 million, with net product sales of $89.7 million for Trokendi XR® and $23.7 million for Oxtellar XR®. Operating earnings reached $45.5 million, showing a 21% growth year-over-year. The company completed the acquisition of a CNS portfolio and established a collaboration with Navitor Pharmaceuticals for SPN-820. It expects net product sales for 2020 to be between $460 million and $500 million, with operating earnings between $90 million and $110 million.
Supernus Pharmaceuticals reported estimated total revenue of $126.7 million for Q2 2020, marking a 21% increase from 2019. The net product sales for Trokendi XR and Oxtellar XR reached $113.4 million, reflecting an 11% increase. This growth was driven partly by $10.6 million from the acquisition of US WorldMeds’ CNS portfolio on June 9, 2020. A conference call to provide detailed results will be held on August 19, 2020.
Supernus Pharmaceuticals (NASDAQ: SUPN) announced a lawsuit against Apotex for infringing on nine patents related to its antiepileptic drug Oxtellar XR. The suit was filed in the U.S. District Court for New Jersey after Apotex submitted an ANDA to the FDA, seeking to market a generic version before patent expiration on April 13, 2027. This legal action allows Supernus a 30-month stay on FDA approval of Apotex's generic. Previously, Supernus successfully defended its patent rights against other generic competitors. The company remains focused on CNS disease treatments.
Supernus Pharmaceuticals (Nasdaq: SUPN) has successfully completed the acquisition of the CNS portfolio from US WorldMeds, enhancing its position in treating CNS diseases, specifically Parkinson's disease. This move seeks to diversify revenue streams and strengthen its market presence. CEO Jack Khattar emphasized the acquisition's strategic importance to expand their business. Supernus continues developing various products for CNS conditions, aiming to improve its financial performance while maintaining a robust balance sheet.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced that its management will present an overview and update during the Jefferies Virtual Healthcare Conference on June 2, 2020, at 4:00 p.m. ET. Investors can arrange virtual meetings with management by contacting the conference coordinator. A live webcast of the presentation will be accessible on the company’s website, with a replay available for 60 days post-conference. Supernus focuses on CNS diseases and markets Trokendi XR® and Oxtellar XR® while developing products for ADHD, treatment-resistant depression, and epilepsy.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced receipt of a Paragraph IV Notice Letter from Apotex regarding an Abbreviated New Drug Application for oxcarbazepine extended-release tablets. The company plans to defend its intellectual property rights proactively, having successfully defended Oxtellar XR against previous generic challengers, Actavis and Twi Pharmaceuticals. Currently, Oxtellar XR is protected by nine patents expiring no sooner than 2027. Supernus continues to develop products targeting central nervous system diseases, including candidates for ADHD and treatment-resistant depression.
Supernus Pharmaceuticals reported its Q1 2020 financial results, achieving $95.0 million in total revenue, an 11% increase over 2019. Net product sales were $92.5 million, also rising by 11%. Operating earnings increased to $29.0 million, a 14% increase year-over-year. The company is on track for the launch of SPN-812 pending FDA approval, with a PDUFA date set for November 8, 2020. Additionally, the acquisition of the CNS portfolio from US WorldMeds is expected to close in Q2 2020, enhancing its neurology portfolio and diversifying revenues.
FAQ
What is the current stock price of Supernus Pharmaceuticals (SUPN)?
What is the market cap of Supernus Pharmaceuticals (SUPN)?
What types of disorders does Supernus Pharmaceuticals focus on?
What are some of the key products developed by Supernus Pharmaceuticals?
What recent collaborations has Supernus Pharmaceuticals announced?
When will Supernus Pharmaceuticals report its financial results for Q4 and the full year of 2023?
What is the significance of Qelbree®?
How does Supernus Pharmaceuticals leverage its proprietary technologies?
What is the main focus of Supernus Pharmaceuticals' ongoing projects?
Who are the key executives at Supernus Pharmaceuticals?
What are the safety concerns related to Qelbree®?
Where can I find more information about Supernus Pharmaceuticals and its products?
